company background image
PODD

InsuletNasdaqGS:PODD Stock Report

Market Cap

US$21.0b

7D

1.3%

1Y

22.0%

Updated

22 Oct, 2021

Data

Company Financials +
PODD fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance0/6
Financial Health3/6
Dividends0/6

PODD Overview

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.

Insulet Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Insulet
Historical stock prices
Current Share PriceUS$304.33
52 Week HighUS$214.93
52 Week LowUS$309.99
Beta0.68
1 Month Change5.67%
3 Month Change10.05%
1 Year Change22.03%
3 Year Change262.17%
5 Year Change722.29%
Change since IPO1,806.83%

Recent News & Updates

Oct 12
Insulet (NASDAQ:PODD) Has A Somewhat Strained Balance Sheet

Insulet (NASDAQ:PODD) Has A Somewhat Strained Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Shareholder Returns

PODDUS Medical EquipmentUS Market
7D1.3%2.6%2.6%
1Y22.0%22.6%31.1%

Return vs Industry: PODD matched the US Medical Equipment industry which returned 22.6% over the past year.

Return vs Market: PODD underperformed the US Market which returned 31.1% over the past year.

Price Volatility

Is PODD's price volatile compared to industry and market?
PODD volatility
PODD Beta0.68
Industry Beta0.88
Market Beta1

Stable Share Price: PODD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: PODD's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20001,900Shacey Petrovichttps://www.insulet.com

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East.

Insulet Fundamentals Summary

How do Insulet's earnings and revenue compare to its market cap?
PODD fundamental statistics
Market CapUS$20.96b
Earnings (TTM)-US$30.50m
Revenue (TTM)US$995.60m

21.1x

P/S Ratio

-687.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PODD income statement (TTM)
RevenueUS$995.60m
Cost of RevenueUS$332.50m
Gross ProfitUS$663.10m
ExpensesUS$693.60m
Earnings-US$30.50m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Nov 04, 2021

Earnings per share (EPS)-0.44
Gross Margin66.60%
Net Profit Margin-3.06%
Debt/Equity Ratio273.6%

How did PODD perform over the long term?

See historical performance and comparison

Valuation

Is Insulet undervalued compared to its fair value and its price relative to the market?

45.66x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: PODD ($304.33) is trading above our estimate of fair value ($118.43)

Significantly Below Fair Value: PODD is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PODD is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: PODD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PODD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PODD is overvalued based on its PB Ratio (45.7x) compared to the US Medical Equipment industry average (4.6x).


Future Growth

How is Insulet forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?

50.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PODD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: PODD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PODD's is expected to become profitable in the next 3 years.

Revenue vs Market: PODD's revenue (18.8% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: PODD's revenue (18.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PODD's Return on Equity is forecast to be low in 3 years time (19.4%).


Past Performance

How has Insulet performed over the past 5 years?

51.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PODD is currently unprofitable.

Growing Profit Margin: PODD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PODD is unprofitable, but has reduced losses over the past 5 years at a rate of 51.3% per year.

Accelerating Growth: Unable to compare PODD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PODD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (36.1%).


Return on Equity

High ROE: PODD has a negative Return on Equity (-6.64%), as it is currently unprofitable.


Financial Health

How is Insulet's financial position?


Financial Position Analysis

Short Term Liabilities: PODD's short term assets ($1.3B) exceed its short term liabilities ($213.3M).

Long Term Liabilities: PODD's short term assets ($1.3B) exceed its long term liabilities ($1.3B).


Debt to Equity History and Analysis

Debt Level: PODD's debt to equity ratio (273.6%) is considered high.

Reducing Debt: PODD's debt to equity ratio has reduced from 624.3% to 273.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if PODD has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PODD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Insulet current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PODD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PODD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PODD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PODD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PODD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Shacey Petrovic (47 yo)

2.75yrs

Tenure

US$7,275,333

Compensation

Ms. Shacey Petrovic has been an Independent Director at Exact Sciences Corporation since July 22, 2020. Ms. Petrovic serves as Director of Alydia Health, Inc. She is the President of Insulet Corporation si...


CEO Compensation Analysis

Compensation vs Market: Shacey's total compensation ($USD7.28M) is below average for companies of similar size in the US market ($USD11.15M).

Compensation vs Earnings: Shacey's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PODD's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: PODD's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PODD insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.9%.


Top Shareholders

Company Information

Insulet Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Insulet Corporation
  • Ticker: PODD
  • Exchange: NasdaqGS
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$20.960b
  • Shares outstanding: 68.87m
  • Website: https://www.insulet.com

Number of Employees


Location

  • Insulet Corporation
  • 100 Nagog Park
  • Acton
  • Massachusetts
  • 1720
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/22 22:58
End of Day Share Price2021/10/22 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.